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Introduction
In the United States, the Department of Health and Human Services and the Food and Drug
Administration have jurisdiction to develop and implement regulations that empower local
committees to approve and monitor all forms of medical research. These committees are
Institutional Review Boards (IRBs) which oversee the scientific, ethical, and regulatory
aspects of research conducted on human subjects. With the increasing complexity of medical
research, there have been increasing federal regulations governing these studies. This is
especially true concerning the conduct of studies collecting genetic data1-4. Institutional
variation in the interpretation and application of these regulations can have significant
impact on the implementation of such studies.
In the present investigation, we assessed variability in IRB review at institutions
participating in the Project CRASH Research Network. This network was formed to conduct
Project CRASH, a large NIH-funded (AR056328) multi-center ED-based study examining
genotypic and phenotypic predictors of pain and psychological outcomes after minor motor
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vehicle collision (MVC). This is one of the first multi-center genetic research protocols
based solely in the Emergency Department (ED).
Material and Methods
Project CRASH enrolls patients who present to the ED after minor MVC. Consenting
patients complete initial interview evaluation in the ED, and a blood sample is obtained in
the ED for subsequent genetic analyses. The purpose of these analyses is to examine alleles
associated with patient recovery characteristics. Patient outcome information is subsequently
obtained 6 weeks, 6 months, and 1 year after MVC via telephone and/or web-based self-
report survey.
We performed an observational study looking at variability in the IRBs reviewing the
Project CRASH protocol. Initial research network institutions include XXX (n=7). Three of
the sites are academic university-based institutions, and four sites are community hospitals
with strong academic affiliations. All sites have an emergency medicine residency training
program.
During the preparation phase of the study, the principle investigator (PI) at each institution
in the research network used a uniform Project CRASH study protocol to prepare their local
IRB application. Each of these sites has a full time, professional research staff, including a
study coordinator who supervises and assists with IRB submissions. In addition, site PIs also
used a prototype IRB application, which contained responses to commonly asked IRB
application questions. Following completion of the IRB approval process at each site, each
site PI was asked to complete a standardized questionnaire which collected information on
the IRB process at their site. This questionnaire collected data including information
regarding institution demographics, original IRB application characteristics, subsequent IRB
correspondence, and time interval between submission and approval.
Descriptive statistics were used to compare IRB approval process characteristics across
participating sites. If initial questionnaire responses were unclear, copies of the original IRB
application and/or correspondence were obtained and reviewed to determine appropriate
categorization.
Results
PIs from all 7 institutions participating in the research network completed the questionnaire.
Characteristics of participating institutions are displayed in Table 1. Among institutions, the
time interval in receiving IRB approval varied between 20-760 days (see figure 1). One site
appeared to be an outlier with time delay to approval of 760 days. After removing this site
from analysis, the median time delay was 101 days (IQR 20-192).
Table 2 describes the number and type of IRB requests for revisions. The most commonly
requested changes were changes to the consent form. No IRB required a separate signature
for use of genetic data or genetic banking on the consent. Again, there were multiple outliers
amongst the IRBs in various topics. Two sites required more than ten changes on the
protocol while the majority of sites requested three or less changes. One IRB required eight
changes on the protocol due to ethical issues while the rest required two or less changes.
Discussion
In the past several decades, the number of genetic studies has exponentially increased. IRBs
have increasingly searched for guidance to aid in the discussion and regulation of these
studies. In 2009, the Infectious Disease Society of America addressed the regulatory burden
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on research and called for a clearer federal guidance and greater use of a centralized IRB
system. This would remove some of the duties of “overloaded” local IRBs.1
Compared to other similar studies, our study had a much greater mean time to IRB approval.
In 2003, McWilliams and colleagues reported variations in the IRB approval process among
the thirty-one sites in their multi-center genetic epidemiology study on cystic fibrosis. In
their study, the mean time for approval after full IRB review was 81 days (range, 13-252).
Our study had a mean 201 days (range, 20-760). Although McWilliams study had a shorter
time interval to approval, there were a far greater number of changes and issues that were
raised during the implementation of their study. This may in part be due to the fact that the
McWilliams study included children.3
Other multi-center ED studies have had much shorter time intervals to IRB approval. In
2006, Mansbach and colleagues reported their difficulties in their multi-center observational
pediatric study investigating bronchiolitis. In their study, the mean time for approval was 42
days (range, 27-61). Again, there were a far greater number of changes and issues as
compared to our study.2 In 2001, Stair and colleagues reported a median time of delay of 38
days (IQR 26-142) in their randomized, placebo-controlled, interventional study
investigating asthma treatment.5
Limitations
One confounding factor is the relatively small number of study sites (seven). In our study,
all sites that agreed to participate in the CRASH study obtained IRB approval. Other similar
studies reported a greater “drop-out” rate and those sites were not included in their
respective final analyses.2, 3 This may have inflated our mean time to approval since we did
not have any sites “drop-out”. The first three sites that entered into the research network had
a much longer time interval to approval as compared to the last four. We do not know
whether the various IRBs discussed this project amongst themselves.
Conclusion
Institutional interpretation of regulations regarding our ED-based genetic study was highly
variable. Although the majority of our results are consistent with other similar published
studies, the mean time interval for approval for this genetic study is far greater than other
reported studies. We hope that the process of IRB approval will become more efficient as
institutions become more familiar with genetic and multi-center ED based studies.
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Table 1
Hospital characteristics (median and interquartile)).
Number of hospital
beds
Number of members on
the IRB committee





Number of days between initial
receipt of IRB application and
final IRB approval
731 (529-900) 30 (20.5-63.5) 8.0(7.0-10.0) 3.5 (2.0-8.2) 105 (21-225)
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Table 2












2.0 (0.0-11) 1.0 (0.0-2.0) 2.0 (0.0-4.0) 1.0 (0.0-1.0) 0 (0.0-1.0) 0 (0.0-0.5) 0 (0.0-3.5) 0 (0.0-4.0)
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